美罗培南-法硼巴坦：抵抗革兰氏阴性菌感染的新武器。
Meropenem-vaborbactam: a new weapon in the war against infections due to resistant Gram-negative bacteria.
机构信息
Department of Pharmacy Services, Michigan Medicine, Ann Arbor, MI 48109, USA.
Department of Pharmacy Services, Sinai-Grace Hospital, Detroit, MI 482351, USA.
出版信息
Future Microbiol. 2018 Jul;13(9):971-983. doi: 10.2217/fmb-2018-0054. Epub 2018 Apr 25.
Abstract
Meropenem-vaborbactam is a fixed-dose combination product of a carbapenem and a cyclic boronic acid β-lactamase inhibitor with potent in vitro activity against Klebsiella pneumoniae carbapenemase-producing carbapenem-resistant Enterobacteriaceae (CRE). The efficacy of meropenem-vaborbactam for the treatment of complicated urinary tract infections and acute pyelonephritis was demonstrated in a Phase III trial (TANGO I). Preliminary data from TANGO II, a separate Phase III study, support the efficacy of meropenem-vaborbactam for the treatment of infections caused by CRE. Overall, meropenem-vaborbactam appears to be safe and well tolerated. It has favorable toxicity, pharmacokinetic and pharmacodynamic profiles compared with other antibiotics with activity against CRE. Meropenem-vaborbactam is an important addition to the current armamentarium of antimicrobial agents with activity against K. pneumoniae carbapenemase-producing CRE.
摘要
美罗培南-法硼巴坦是一种碳青霉烯类药物和一种环状硼酸β-内酰胺酶抑制剂的固定剂量组合产品，对产碳青霉烯酶的碳青霉烯类耐药肠杆菌科（CRE）具有强大的体外活性。美罗培南-法硼巴坦治疗复杂性尿路感染和急性肾盂肾炎的疗效在 III 期临床试验（TANGO I）中得到了证实。来自单独的 III 期研究 TANGO II 的初步数据支持美罗培南-法硼巴坦治疗 CRE 引起的感染的疗效。总的来说，美罗培南-法硼巴坦似乎安全且耐受良好。与其他具有抗 CRE 活性的抗生素相比，它具有良好的毒性、药代动力学和药效学特征。美罗培南-法硼巴坦是对抗产碳青霉烯酶肺炎克雷伯菌的现有抗菌药物武器库的重要补充。
相似文献
1
Meropenem-vaborbactam: a new weapon in the war against infections due to resistant Gram-negative bacteria.
Future Microbiol. 2018 Jul;13(9):971-983. doi: 10.2217/fmb-2018-0054. Epub 2018 Apr 25.
2
Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
Drugs. 2018 Jan;78(1):65-98. doi: 10.1007/s40265-017-0851-9.
3
Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections.
Drugs. 2018 Aug;78(12):1259-1270. doi: 10.1007/s40265-018-0966-7.
4
Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with Meropenem.
Antimicrob Agents Chemother. 2018 Dec 21;63(1). doi: 10.1128/AAC.01659-18. Print 2019 Jan.
5
Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant Enterobacteriaceae.
Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01446-17. Print 2018 Jan.
6
Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in a Murine Model of Pyelonephritis.
Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01439-17. Print 2018 Jan.
7
Meropenem-vaborbactam for adults with complicated urinary tract and other invasive infections.
Expert Rev Anti Infect Ther. 2018 Dec;16(12):865-876. doi: 10.1080/14787210.2018.1542300. Epub 2018 Nov 5.
8
Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem-resistant Enterobacteriaceae.
Pharmacotherapy. 2018 Apr;38(4):444-461. doi: 10.1002/phar.2092. Epub 2018 Mar 28.
9
Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae.
Eur J Clin Microbiol Infect Dis. 2018 Aug;37(8):1411-1419. doi: 10.1007/s10096-018-3260-4. Epub 2018 Apr 19.
10
An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam.
Infect Dis Ther. 2020 Dec;9(4):769-784. doi: 10.1007/s40121-020-00344-z. Epub 2020 Oct 6.
引用本文的文献
1
Strategic re-engineering of antibiotics.
Nat Rev Bioeng. 2025 Mar;3(3):213-229. doi: 10.1038/s44222-024-00250-w. Epub 2024 Oct 15.
2
Difficult-to-Treat Infections in Critically Ill Patients: A Comprehensive Review and Treatment Proposal.
Antibiotics (Basel). 2025 Feb 11;14(2):178. doi: 10.3390/antibiotics14020178.
3
Tackling the outer membrane: facilitating compound entry into Gram-negative bacterial pathogens.
NPJ Antimicrob Resist. 2023 Dec 20;1(1):17. doi: 10.1038/s44259-023-00016-1.
4
A systematic review of efficacy and safety of newer drugs approved from 2016 to 2023 for the treatment of complicated urinary tract infections.
Ann Med. 2024 Dec;56(1):2403724. doi: 10.1080/07853890.2024.2403724. Epub 2024 Nov 12.
5
Meropenem/Vaborbactam-A Mechanistic Review for Insight into Future Development of Combinational Therapies.
Antibiotics (Basel). 2024 May 21;13(6):472. doi: 10.3390/antibiotics13060472.
6
Change in Diagnosis of Infection in the Treatment-Failure Era.
Antibiotics (Basel). 2024 Apr 12;13(4):357. doi: 10.3390/antibiotics13040357.
7
Boronic acid inhibitors of penicillin-binding protein 1b: serine and lysine labelling agents.
J Enzyme Inhib Med Chem. 2024 Dec;39(1):2305833. doi: 10.1080/14756366.2024.2305833. Epub 2024 Feb 27.
8
New Antibiotics Against Multidrug-Resistant Gram-Negative Bacteria in Liver Transplantation: Clinical Perspectives, Toxicity, and PK/PD Properties.
Transpl Int. 2024 Feb 1;37:11692. doi: 10.3389/ti.2024.11692. eCollection 2024.
9
Novel Beta Lactam Antibiotics for the Treatment of Multidrug-Resistant Gram-Negative Infections in Children: A Narrative Review.
Microorganisms. 2023 Jul 13;11(7):1798. doi: 10.3390/microorganisms11071798.
10
Chemical Basis of Combination Therapy to Combat Antibiotic Resistance.
JACS Au. 2023 Jan 31;3(2):276-292. doi: 10.1021/jacsau.2c00532. eCollection 2023 Feb 27.
本文引用的文献
1
Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial.
JAMA. 2018 Feb 27;319(8):788-799. doi: 10.1001/jama.2018.0438.
2
Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment.
Antimicrob Agents Chemother. 2018 Feb 23;62(3). doi: 10.1128/AAC.02103-17. Print 2018 Mar.
3
Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in -Harboring Klebsiella pneumoniae Sequence Type 307 Isolates.
Antimicrob Agents Chemother. 2018 Feb 23;62(3). doi: 10.1128/AAC.02101-17. Print 2018 Mar.
4
Activity of Simulated Human Dosage Regimens of Meropenem and Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in an Hollow-Fiber Model.
Antimicrob Agents Chemother. 2018 Jan 25;62(2). doi: 10.1128/AAC.01969-17. Print 2018 Feb.
5
Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae.
Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01904-17. Print 2018 Jan.
6
Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae.
Antimicrob Agents Chemother. 2017 Nov 22;61(12). doi: 10.1128/AAC.01694-17. Print 2017 Dec.
7
Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.
Clin Infect Dis. 2018 Jan 6;66(2):163-171. doi: 10.1093/cid/cix783.
8
Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae.
Antimicrob Agents Chemother. 2017 Oct 24;61(11). doi: 10.1128/AAC.01443-17. Print 2017 Nov.
9
Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae.
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.00567-17. Print 2017 Sep.
10
Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia.
Antimicrob Agents Chemother. 2017 Jul 25;61(8). doi: 10.1128/AAC.00883-17. Print 2017 Aug.
Zotero 插件